The_DT
peri-kappa_NN
B_NN
site_NN
mediates_VBZ
human_JJ
immunodeficiency_NN
virus_NN
type_NN
2_CD
enhancer_NN
activation_NN
in_IN
monocytes_NNS
but_CC
not_RB
in_IN
T_NN
cells_NNS
._.

Human_JJ
immunodeficiency_NN
virus_NN
type_NN
2_CD
-LRB-_-LRB-
HIV-2_NN
-RRB-_-RRB-
,_,
like_IN
HIV-1_NN
,_,
causes_VBZ
AIDS_NN
and_CC
is_VBZ
associated_VBN
with_IN
AIDS_NN
cases_NNS
primarily_RB
in_IN
West_NNP
Africa_NNP
._.

HIV-1_NN
and_CC
HIV-2_NN
display_VBP
significant_JJ
differences_NNS
in_IN
nucleic_JJ
acid_NN
sequence_NN
and_CC
in_IN
the_DT
natural_JJ
history_NN
of_IN
clinical_JJ
disease_NN
._.

Consistent_JJ
with_IN
these_DT
differences_NNS
,_,
we_PRP
have_VBP
previously_RB
demonstrated_VBN
that_IN
the_DT
enhancer\/promoter_NN
region_NN
of_IN
HIV-2_NN
functions_VBZ
quite_RB
differently_RB
from_IN
that_DT
of_IN
HIV-1_NN
._.

Whereas_IN
activation_NN
of_IN
the_DT
HIV-1_NN
enhancer_NN
following_VBG
T-cell_NN
stimulation_NN
is_VBZ
mediated_VBN
largely_RB
through_IN
binding_NN
of_IN
the_DT
transcription_NN
factor_NN
NF-kappa_NN
B_NN
to_TO
two_CD
adjacent_JJ
kappa_NN
B_NN
sites_NNS
in_IN
the_DT
HIV-1_NN
long_JJ
terminal_JJ
repeat_NN
,_,
activation_NN
of_IN
the_DT
HIV-2_NN
enhancer_NN
in_IN
monocytes_NNS
and_CC
T_NN
cells_NNS
is_VBZ
dependent_JJ
on_IN
four_CD
cis-acting_JJ
elements_NNS
:_:
a_DT
single_JJ
kappa_NN
B_NN
site_NN
,_,
two_CD
purine-rich_JJ
binding_NN
sites_NNS
,_,
PuB1_NN
and_CC
PuB2_NN
,_,
and_CC
a_DT
pets_NN
site_NN
._.

We_PRP
have_VBP
now_RB
identified_VBN
a_DT
novel_JJ
cis-acting_JJ
element_NN
within_IN
the_DT
HIV-2_NN
enhancer_NN
,_,
immediately_RB
upstream_RB
of_IN
the_DT
kappa_NN
B_NN
site_NN
,_,
designated_VBN
peri-kappa_NN
B_NN
._.

This_DT
site_NN
is_VBZ
conserved_VBN
among_IN
isolates_NNS
of_IN
HIV-2_NN
and_CC
the_DT
closely_RB
related_VBN
simian_JJ
immunodeficiency_NN
virus_NN
,_,
and_CC
transfection_NN
assays_NNS
show_VBP
this_DT
site_NN
to_TO
mediate_VB
HIV-2_NN
enhancer_NN
activation_NN
following_VBG
stimulation_NN
of_IN
monocytic_JJ
but_CC
not_RB
T-cell_NN
lines_NNS
._.

This_DT
is_VBZ
the_DT
first_JJ
description_NN
of_IN
an_DT
HIV-2_NN
enhancer_NN
element_NN
which_WDT
displays_VBZ
such_JJ
monocyte_NN
specificity_NN
,_,
and_CC
no_DT
comparable_JJ
enhancer_NN
element_NN
has_VBZ
been_VBN
clearly_RB
defined_VBN
for_IN
HIV-1_NN
._.

While_IN
a_DT
nuclear_JJ
factor_NN
-LRB-_-LRB-
s_NNS
-RRB-_-RRB-
from_IN
both_CC
peripheral_JJ
blood_NN
monocytes_NNS
and_CC
T_NN
cells_NNS
binds_VBZ
the_DT
peri-kappa_NN
B_NN
site_NN
,_,
electrophoretic_JJ
mobility_NN
shift_NN
assays_NNS
suggest_VBP
that_IN
either_CC
a_DT
different_JJ
protein_NN
binds_VBZ
to_TO
this_DT
site_NN
in_IN
monocytes_NNS
versus_CC
T_NN
cells_NNS
or_CC
that_IN
the_DT
protein_NN
recognizing_VBG
this_DT
enhancer_NN
element_NN
undergoes_VBZ
differential_JJ
modification_NN
in_IN
monocytes_NNS
and_CC
T_NN
cells_NNS
,_,
thus_RB
supporting_VBG
the_DT
transfection_NN
data_NNS
._.

Further_RB
,_,
while_IN
specific_JJ
constitutive_JJ
binding_NN
to_TO
the_DT
peri-kappa_NN
B_NN
site_NN
is_VBZ
seen_VBN
in_IN
monocytes_NNS
,_,
stimulation_NN
with_IN
phorbol_NN
esters_NNS
induces_VBZ
additional_JJ
,_,
specific_JJ
binding_NN
._.

Understanding_VBG
the_DT
monocyte-specific_JJ
function_NN
of_IN
the_DT
peri-kappa_NN
B_NN
factor_NN
may_MD
ultimately_RB
provide_VB
insight_NN
into_IN
the_DT
different_JJ
role_NN
monocytes_NNS
and_CC
T_NN
cells_NNS
play_VBP
in_IN
HIV_NN
pathogenesis_NN
._.

